Spotlight on hTERT Complex Regulation in Cutaneous T-Cell Lymphomas

Genes (Basel). 2023 Feb 8;14(2):439. doi: 10.3390/genes14020439.

Abstract

As a major cancer hallmark, there is a sustained interest in understanding the telomerase contribution to carcinogenesis in order to therapeutically target this enzyme. This is particularly relevant in primary cutaneous T-cell lymphomas (CTCL), a malignancy showing telomerase dysregulation with few investigative data available. In CTCL, we examined the mechanisms involved in telomerase transcriptional activation and activity regulation. We analyzed 94 CTCL patients from a Franco-Portuguese cohort, as well as 8 cell lines, in comparison to 101 healthy controls. Our results showed that not only polymorphisms (SNPs) located at the promoter of human telomerase reverse transcriptase (hTERT) gene (rs2735940 and rs2853672) but also an SNP located within the coding region (rs2853676) could influence CTCL occurrence. Furthermore, our results sustained that the post-transcriptional regulation of hTERT contributes to CTCL lymphomagenesis. Indeed, CTCL cells present a different pattern of hTERT spliced transcripts distribution from the controls, mostly marked by an increase in the hTERT β+ variants proportion. This increase seems to be associated with CTCL development and progression. Through hTERT splicing transcriptome modulation with shRNAs, we observed that the decrease in the α-β+ transcript induced a decrease in the cell proliferation and tumorigenic capacities of T-MF cells in vitro. Taken together, our data highlight the major role of post-transcriptional mechanisms regulating telomerase non canonical functions in CTCL and suggest a new potential role for the α-β+ hTERT transcript variant.

Keywords: CTCL; SNP; hTERT; promoter mutations; splicing variants; telomerase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line
  • Gene Expression Regulation
  • Humans
  • Lymphoma, T-Cell, Cutaneous*
  • Promoter Regions, Genetic
  • Telomerase* / genetics

Substances

  • Telomerase
  • TERT protein, human

Grants and funding

J.R. received funding from Programme Hubert Curien PESSOA, Programme d’Actions Universitaires Intégrées Luso-Françaises (PAUILF) and ERASMUS+. FCT (Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior) supported a PhD grant to RP (SFRH/BD/111321/2015) and AP (SFRH/BD/110617/2015). AC was supported by grants from Programme Hubert Curien CEDRE and ERASMUS+. This work was sponsored by grants from French Society of Dermatology (SFD), Ligue Contre le Cancer Comité Dordogne and foundation for cancer research (ARC). This article is partly supported by the project “Cancer Research on Therapy Resistance: From Basic Mechanisms to Novel Targets”—NORTE-01-0145-FEDER-000051, supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). Further funding (in part) by Programa Operacional Regional do Norte and co-funded by European Regional Development Fund under the project “The Porto Comprehensive Cancer Center” with the reference NORTE-01-0145-FEDER-072678—Consórcio PORTO.CCC—Porto.Comprehensive Cancer Center Raquel Seruca.